Anticancer activity of methyl-substituted oxaliplatin analogs

Molecular Pharmacology

Volumn 81, Issue 5, 2012, Pages 719-728

  Jungwirth, Ute ^a,b,c   Xanthos, Dimitris N ^b   Gojo, Johannes ^a,b,c   Bytzek, Anna K ^d   Körner, Wilfried ^d   Heffeter, Petra ^a,b,c   Abramkin, Sergey A ^d   Jakupec, Michael A ^c,d   Hartinger, Christian G ^c,d   Windberger, Ursula ^b   Galanski, Markus ^c,d   Keppler, Bernhard K ^c,d   Berger, Walter ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Research Platform Translational Cancer Therapy Research Vienna   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

[4 METHYL 1,2 CYCLOHEXANEDIAMIN]OXALATOPLATINUM; ANTINEOPLASTIC METAL COMPLEX; KP 1537; KP 1691; OXALIPLATIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG ACCUMULATION; ENANTIOMER; GENE MUTATION; HUMAN; HUMAN CELL; HYPERALGESIA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; STEREOISOMERISM; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DNA; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; ORGANOPLATINUM COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859991368     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077321     Document Type: Article

References (43)

1. Abramkin SA, Jungwirth U, Valiahdi SM, Dworak C, Habala L, Meelich K, Berger W, Jakupec MA, Hartinger CG, Nazarov AA, et al. (2010) {(1R,2R,4R)-4-Methyl- 1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. J Med Chem 53:7356-7364.
2. Abu Lila AS, Doi Y, Nakamura K, Ishida T, and Kiwada H (2010) Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release 142:167-173.
3. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, and Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25-32.
4. Ali BH (2010) Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin Pharmacol Toxicol 106:272-279.
5. Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM, and Augenlicht LH (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931-1946. (Pubitemid 40065523)
6. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, and Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34: 368-377.
7. Berger W, Elbling L, Minai-Pour M, Vetterlein M, Pirker R, Kokoschka EM, and Micksche M (1994) Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int J Cancer 59:717-723. (Pubitemid 24358598)
8. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, and Wiemer EA (2010) Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898-908.
9. Buss I, Garmann D, Galanski M, Weber G, Kalayda GV, Keppler BK, and Jaehde U (2011) Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes? J Inorg Biochem 105:709-717.
10. Chaney SG, Campbell SL, Bassett E, and Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:3-11. (Pubitemid 39656106)
11. Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, et al. (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 3:266-278.
12. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, et al. (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7:3408-3419.
13. Galanski M, Yasemi A, Slaby S, Jakupec MA, Arion VB, Rausch M, Nazarov AA, and Keppler BK (2004) Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. Eur J Med Chem 39:707-714. (Pubitemid 38970085)
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, and Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30. (Pubitemid 41095110)
15. Habala L, Galanski M, Yasemi A, Nazarov AA, von Keyserlingk NG, and Keppler BK (2005) Synthesis and structure-activity relationships of mono- and dialkylsubstituted oxaliplatin derivatives. Eur J Med Chem 40:1149-1155. (Pubitemid 41446286)
16. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, and Jodrell DI (2004) Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl downregulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169-178. (Pubitemid 39193691)
17. Heffeter P, Böck K, Atil B, Reza Hoda MA, Körner W, Bartel C, Jungwirth U, Keppler BK, Micksche M, Berger W, et al. (2010) Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem 15:737-748.
18. Heffeter P, Jakupec MA, Körner W, Chiba P, Pirker C, Dornetshuber R, Elbling L, Sutterlüty H, Micksche M, Keppler BK, et al. (2007) Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 73:1873-1886. (Pubitemid 46677901)
19. Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, and Berger W (2008) Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 11:1-16.
20. Jong NN, Nakanishi T, Liu JJ, Tamai I, and McKeage MJ (2011) Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338:537-547.
21. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, and Heffeter P (2011) Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal 15:1085-1127.
22. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
23. Luo FR, Wyrick SD, and Chaney SG (1999) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 13:159-169. (Pubitemid 129705388)
24. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30:1147-1158.
25. McWhinney SR, Goldberg RM, and McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8:10-16.
26. Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, Failli P, Preti D, Marchetti N, Cavazzini A, et al. (2011) Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152:1621-1631.
27. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, and Creaven PJ (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177-184.
28. Pizarro AM and Sadler PJ (2009) Unusual DNA binding modes for metal anticancer complexes. Biochimie 91:1198-1211.
29. Rappel C, Galanski M, Yasemi A, Habala L, and Keppler BK (2005) Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis 26:878-884. (Pubitemid 40424920)
30. Reithofer MR, Valiahdi SM, Jakupec MA, Arion VB, Egger A, Galanski M, and Keppler BK (2007) Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem 50:6692-6699. (Pubitemid 350309106)
31. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, and Cavaletti G (2011) Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin- based chemotherapy in mice. Mol Pain 7:29.
32. Rosenberg B, Vancamp L, and Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699.
33. Rosenberg B, VanCamp L, Trosko JE, and Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385-386.
34. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, and Oishi R (2009) Oxaliplatin- induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 147:165-174.
35. Shah N and Dizon DS (2009) New-generation platinum agents for solid tumors. Future Oncol 5:33-42.
36. Stordal B, Pavlakis N, and Davey R (2007) Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 33:347-357. (Pubitemid 46760527)
37. Ta LE, Low PA, and Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 5:9.
38. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482-491.
39. Wang D and Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320. (Pubitemid 41130944)
40. Wang X (2010) Fresh platinum complexes with promising antitumor activity. Anticancer Agents Med Chem 10:396-411.
41. Webster RG, Brain KL, Wilson RH, Grem JL, and Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146:1027-1039. (Pubitemid 41722176)
42. Woynarowski JM, Chapman WG, Napier C, Herzig MC, and Juniewicz P (1998) Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777. (Pubitemid 28523169)
43. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, and Kroemer G (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16:3100-3104.